E-MTAB-11476
Ontology highlight
ABSTRACT:
PROVIDER: E-MTAB-11476 | ExpressionAtlas | 2025-01-23
REPOSITORIES: ExpressionAtlas
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| E-MTAB-11476-analysis-methods.tsv | Tabular | |||
| E-MTAB-11476-analytics.tsv | Tabular | |||
| E-MTAB-11476-atlasExperimentSummary.Rdata | Rdata | |||
| E-MTAB-11476-configuration.xml | Xml | |||
| E-MTAB-11476-g2_g1-mvaPlot.png | Other |
Items per page: 5 1 - 5 of 22 |
Similar Datasets
Project description:Axon Guidance Receptor ROBO3 Modulates Subtype Identity and Prognosis via AXL-associated Inflammatory Network in Pancreatic Cancer
| PRJEB51145 | ENA
Project description:MUC13 has emerged as a critical molecular player that is involved in tumorigenesis, cancer progression, metastasis and evade immune surveillance, including in pancreatic cancer. In this report, we have identified MUC13 molecular interactome using an integrated immunoprecipitation and liquid chromatography mass spectrometry (IP-LCMS) technique and systems network biology approach to determine its functional protein-protein interaction network and its associated oncogenic mechanisms. This study reveals total 54 key interactor proteins (CDK1, CTNND1, Caludin-1, ErbB3-binding protein 1, Basic transcription factor 3 and Tight junction protein 1 protein etc) of MUC13. Interestingly majority of the interacting proteins were found to be associated with oncogenic and immune checkpoint pathways. These proteins are involved in the regulation of PD1/PD-L1, T-cell receptor signaling, and post-translational protein processing and modifications in the endoplasmic reticulum. This study also revealed that MUC13 might be involved in other cellular processes such as apoptosis, autophagy, senescence, calcium signaling, microRNA activity, lysosomal function, and diabetic cardiomyopathy. Taken together, this study for the first time elucidated MUC13 associated molecular interactome that might be involved in pancreatic cancer progression and metastasis. This study will help to develop new strategies to intervene pancreatic cancer progression via disrupting MUC13 associated oncogenic molecular network.
2025-11-15 | PXD070763 | JPOST Repository
Project description:Using an inducible, inflammatory model of breast cellular transformation, we describe the transcriptional regulatory network mediated by STAT3, NF-kB, and AP-1 factors on a genomic scale. These regulators form transcriptional complexes that directly regulate the expression of hundreds of genes in oncogenic pathways, such as cell proliferation, metastasis, angiogenesis, apoptosis and metabolism, via a positive feedback loop. This inflammatory feedback loop and associated network, which function to various extents in many types of cancer cells and patient tumors, is the basis for an “inflammation” index that defines cancer types by functional criteria. The inflammation index is negatively correlated with expression of genes involved in DNA metabolism, and transformation is associated with genome instability. Inflammatory tumors are preferentially associated with infiltration immune cells that might be recruited to the site of the tumor via inflammatory molecules produced by the cancer cells.
2018-06-11 | GSE115597 | GEO
Project description:Therapy resistance and resultant relapse remain key challenges in pancreatic cancer, and are in part driven by the inherent heterogeneity of the tumor that prevents effective targeting of all malignant cells. Here we utilized a combination of RNA-seq, ChIP-seq and genome-wide CRISPR screening to systematically map the dependencies of pancreatic cancer stem cells, highly drug resistant cells that are also enriched in the capacity to drive progression 1-4 . Integration of these data revealed an unexpected role for immuno-regulatory genes in stem cell self-renewal and maintenance in KP f/f C tumors. In particular, Retinoic acid receptor-related orphan receptor gamma (ROR g) , a nuclear hormone receptor known for its role in inflammatory cytokine responses and T cell differentiation 5,6 , emerged as a key regulator of stem cells. ROR g expression rose with pancreatic cancer progression, and its inhibition via genetic approaches or small molecule inhibitors led to a striking defect in pancreatic cancer growth in vitro and in vivo. Collectively, these data reveal an unexpected co-option of immuno-regulatory signals by pancreatic cancer stem cells, and suggest that therapeutics currently being used for autoimmune indications should be considered for treatment of pancreatic cancer.
2019-06-18 | GSE113712 | GEO
Project description:Pancreatic cancer is characterized by a high frequency of cachexia, pain and neural invasion (N-inv). Neural damage is occurred by N-inv and modulates pain and muscle atrophy via the activation of astrocyte in the connected spine. The activated astrocyte by N-inv, thus, may affect cachexia in pancreatic cancer. Clinical studies in patients and autopsy cases with pancreatic cancer have revealed that N-inv is related to cachexia and astrocytic activation. We established a novel murine model of cancer cachexia using N-inv of human pancreatic cancer cells. Mice with N-inv showed a loss of body weight, skeletal muscle, and fat mass without appetite loss, which are compatible with an animal model of cancer cachexia. Activation of astrocytes in the spinal cord connected with N-inv was observed in our model. Experimental cachexia was suppressed by disrupting neural routes or inhibiting the activation of astrocytes. These data provide the first evidence that N-inv induces cachexia via astrocytic activation of neural route in pancreatic cancer. We produced neural invasion (N-inv) model using intraneural injection of Capan-1 cells to left sciatic nerve of male SCID mouse. For controls, subcutaneous model (SC) and PBS model were produced. Microarray analysis was performed using the first lumbar cord (L1) from PBS, SC, and N-inv mice at 6 w (n = 2 each).
2011-12-07 | E-GEOD-34189 | biostudies-arrayexpress
Project description:Chromatin accessibility plays an essential role in controlling cellular identity and the therapeutic response of human cancers. However, the chromatin accessibility landscape and gene regulatory network of pancreatic cancer are largely uncharacterized. Here, we integrate the chromatin accessibility profiles of 84 pancreatic cancer organoid lines with whole-genome sequencing data, transcriptomic sequencing data and the results of drug sensitivity analysis of 283 epigenetic-related chemicals and 5 chemotherapeutic drugs. We identify distinct transcription factors that distinguish molecular subtypes of pancreatic cancer, predict numerous chromatin accessibility peaks associated with gene regulatory networks, discover novel regulatory noncoding mutations with potential as cancer drivers, and reveal the chromatin accessibility signatures associated with drug sensitivity. These results not only provide the chromatin accessibility atlas of pancreatic cancer but also suggest a systematic approach to comprehensively understand the gene regulatory network of pancreatic cancer in order to advance diagnosis and potential personalized medicine applications.
2022-02-23 | GSE195623 | GEO
Project description:Using an inducible, inflammatory model of breast cellular transformation, we describe the transcriptional regulatory network mediated by STAT3, NF-kB, and AP-1 factors on a genomic scale. These regulators form transcriptional complexes that directly regulate the expression of hundreds of genes in oncogenic pathways, such as cell proliferation, metastasis, angiogenesis, apoptosis and metabolism, via a positive feedback loop. This inflammatory feedback loop and associated network, which function to various extents in many types of cancer cells and patient tumors, is the basis for an “inflammation” index that defines cancer types by functional criteria. The inflammation index is negatively correlated with expression of genes involved in DNA metabolism, and transformation is associated with genome instability. Inflammatory tumors are preferentially associated with infiltration immune cells that might be recruited to the site of the tumor via inflammatory molecules produced by the cancer cells.
2018-06-11 | GSE115598 | GEO
Project description:<p>The involvement of membrane-bound solute carriers (SLCs) in neoplastic transdifferentiation processes is poorly defined. Here, we examined changes in the SLC landscape during epithelial-mesenchymal transition (EMT) of pancreatic cancer cells. We show that two SLCs from the organic anion/cation transporter family, SLC22A10 and SLC22A15, favor EMT via interferon (IFN) α and γ signaling activation of receptor tyrosine kinase-like orphan receptor 1 (ROR1) expression. In addition, SLC22A10 and SLC22A15 allow tumor cell accumulation of glutathione to support EMT via the IFNα/γ-ROR1 axis. Moreover, a pan-SLC22A inhibitor lesinurad reduces EMT-induced metastasis and gemcitabine chemoresistance to prolong survival in mouse models of pancreatic cancer, thus identifying new vulnerabilities for human PDAC.</p>
2021-10-15 | MTBLS1925 | MetaboLights
Project description:Pancreatic cancer is projected to become the second leading cause of cancer-related deaths globally by 2030, yet effective therapeutic options remain limited. Within the pancreatic cancer tumor microenvironment (TME), tumor-associated macrophages (TAMs) secrete interleukin-1 beta (IL-1β), promoting cancer progression while suppressing type I interferons (IFN-I), which is critical for effective tumor treatment. Utilizing the convolutional neural network (CNN)-based DLINP model developed in our laboratory, we identified Co68—an effective metal catalyst featuring a Phosphine-Nitrogen-Phosphine (PNP)-chelated CoCl₂ complex—as a promising candidate to modulate these immune pathways. In preclinical animal models, Co68 demonstrated superior antitumor efficacy compared to the STING agonist DMXAA and showed enhanced therapeutic effects when combined with PD-1 blockade. Single-cell RNA sequencing (scRNA-seq) revealed that Co68 reprograms TAMs to express interferon-stimulated genes (ISGs), attenuates pro-inflammatory cytokine secretion, and disrupts the IL-1β-PGE2 feedback loop, thereby facilitating the recruitment of NK and cytotoxic CD8+ T cells into the TME. Mechanistically, Co68 activates the IFN-I signaling pathway through the TLR4-TRIF-IFN-I axis and weakens inflammation via the TLR4-SYK-STAT1 pathway. Collectively, these findings highlight the therapeutic potential of Co68, derived from PNP-pincer chemistry, to reshape immune dynamics within the pancreatic cancer TME, positioning it as a promising candidate for innovative immunotherapy strategies.
2025-02-09 | GSE288553 | GEO
Project description:HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer
| PRJNA732187 | ENA